Current disease status-Recurrent cancer - Page 14 of 19 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Ureteral injuries during colorectal surgery

Ureteral injuries during colorectal surgery

Posted by on Mar 22, 2014 in Colorectal cancer | 0 comments

In a nutshell This study analyzed the incidence and risk of ureteral injuries following colorectal surgery. Some background Colorectal surgery is often required to treat cancer of the colon or the rectum. Although all surgeries carry an inherent risk, the ureters (thin tubes connecting the kidneys and the bladder) are especially vulnerable to...

Read More

KRAS mutations and the effectiveness of oxaliplatin-based chemotherapy

KRAS mutations and the effectiveness of oxaliplatin-based chemotherapy

Posted by on Mar 21, 2014 in Colorectal cancer | 0 comments

In a nutshell This study evaluated survival benefit with the use of oxaliplatin (Eloxatin) in relation to KRAS gene status among patients with metastatic colorectal cancer. Some background Metastatic colorectal cancer (cancer that has spread from the large intestine to distant organs and tissues) is often treated by a combination of chemotherapy...

Read More

Circulating tumor DNA as a new biomarker

Circulating tumor DNA as a new biomarker

Posted by on Mar 19, 2014 in Breast cancer | 0 comments

In a nutshell This trial investigated the significance of circulating tumor DNA as a biomarker for monitoring response to treatment among metastatic breast cancer patients.  Some background The management of metastatic breast cancer requires frequent monitoring of response to treatment in order to avoid ineffective therapies and prevent...

Read More

PV-10 therapy reviewed

PV-10 therapy reviewed

Posted by on Mar 15, 2014 in Melanoma | 0 comments

In a nutshell This article reviewed the available literature on the development, use and potential benefit of PV-10 in the treatment of spreading melanoma. Some background Spreading, or in-transit, melanoma often presents with lesions along the course of the migrating cancerous cells. The management of in-transit melanoma is challenging, since...

Read More

Chemotherapy outcomes depending on cancer type

Chemotherapy outcomes depending on cancer type

Posted by on Jan 3, 2014 in Lung cancer | 0 comments

In a nutshell This clinical trial compared the efficacy and safety of a combined chemotherapy regimen of nab-paclitaxel (Abraxane) plus carboplatin (Paraplatin) versus solvent-based paclitaxel (Taxol) plus carboplatin in patients with advanced non-small-cell lung cancer (NSCLC) basing on the microscopic appearance of the cancer tissue...

Read More

Late intestinal adverse effects following radiotherapy

Posted by on Dec 26, 2013 in Prostate cancer | 0 comments

In a nutshell This review analyzed recent publications investigating the late intestinal adverse effects following radiotherapy treatments. Some background Radiotherapy is frequently used in the treatment of prostate cancer. Although radiation techniques have improved over recent years, radiotherapy still commonly causes intestinal adverse events....

Read More

Hormonal therapy and risk of heart disease

Hormonal therapy and risk of heart disease

Posted by on Dec 13, 2013 in Prostate cancer | 0 comments

In a nutshell The present study evaluated the effects of hormonal therapy drugs on cardiovascular events in patients with prostate cancer.  Some background Testosterone (a type of androgen hormone which controls the development and maintenance of male reproductive organs) stimulates the growth of cells in the prostate gland, including...

Read More

The amazing regenerating liver: two-step surgery can increase survival after liver metastasis

Posted by on Dec 10, 2013 in Colorectal cancer | 0 comments

In a nutshell This study examined the safety and efficacy of a two-step hepatectomy combined with hepatic artery infusion chemotherapy as treatment for liver-spread colorectal cancer. Some background A common location for metastasis (spread) of colorectal cancer is the liver. Surgical removal of the liver tumor (hepatectomy) can increase survival...

Read More

More risk with regorafenib

More risk with regorafenib

Posted by on Dec 6, 2013 in Colorectal cancer | 0 comments

In a nutshell This study examined whether there is an increased risk of hypertension among cancer patients being treated with regorafenib (Stivarga). Some background Vascular endothelial growth factor receptors (VEGF-r) are complexes on the surface of cells which stimulate the growth of new blood vessels, and are crucial for cancer growth and...

Read More